Journal article

Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Pericarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrenie : un essai d'efficacite de 24 semaines, a double insu, randomise et controle par placebo

Alyna Turner, Andrea Baker, Olivia M Dean, Adam J Walker, Seetal Dodd, Susan M Cotton, James G Scott, Bianca E Kavanagh, Melanie M Ashton, Ellie Brown, John J McGrath, Michael Berk

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE | SAGE PUBLICATIONS INC | Published : 2021

Abstract

OBJECTIVES: Garcinia mangostana Linn. ("mangosteen") pericarp contains bioactive compounds that may target biological pathways implicated in schizophrenia. We conducted a double-blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp, compared to placebo, in the treatment of schizophrenia. METHODS: People diagnosed with schizophrenia or schizoaffective disorder (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition), recruited across 2 sites (Brisbane and Victoria, Australia), were randomized to receive 24 weeks of adjunctive mangosteen pericarp (1,000 mg/day) or matched placebo. The primary outcome measure was the Positive and Negat..

View full abstract